Why is Hims & Hers Health stock down today? FTC and litigation headlines, key support to watch

Traders Union
All News
Stocks
Hims & Hers Health drops 6.05% today

Highlights

The FTC sued Hims & Hers Health for alleged deceptive privacy and billing practices, raising regulatory and legal risks for the company.
Hagens Berman began investigating Hims & Hers Health’s compliance and disclosures, adding to market concerns about governance and reputation.
Shares of Hims & Hers Health fell 6.05% to $29.83 with strong bearish momentum and a projected price range of $27.7 to $31.96 driven by prevailing negative technical signals.

Legal and governance risks intensify as FTC suit triggers scrutiny

On July 29, 2026, the FTC filed a lawsuit against Hims & Hers Health alleging deceptive privacy and billing practices, including claims that customers were charged for prescriptions before seeing a provider and that cancellation paths were hidden or obstructed. This regulatory action introduces heightened legal risk and escalates uncertainty around the company’s operational practices and potential future liabilities. Following the announcement, the shareholder litigation firm Hagens Berman initiated an investigation into Hims & Hers Health’s compliance and financial disclosures, according to Prnewswire, intensifying market concerns over potential governance and reputational impacts.

Downside momentum builds as technicals breach key support levels

On the technical front, HIMS is positioned below both the MA-20 and MA-50 on the hourly chart, but holds above the longer-term MA-200 support at $28.71. Immediate resistance is established at $32.04, marked by the Ichimoku Kijun. Momentum remains negative, with the RSI at 37.13 and MACD confirming a Sell signal. ADX reads as Neutral, while indicators such as Stoch RSI, CCI, and Bull/Bear Power all highlight oversold conditions and sustained seller dominance intraday. The Awesome Oscillator also points lower, in line with today's decline.

Limited rebound prospects as bearish setup and range dominate outlook

Over the next few sessions, HIMS is expected to trade within the $27.7 to $31.96 volatility band. The probability of a bullish reversal is limited at 26%, while continuation to the downside is favored at 74%. If the price remains within this corridor, a period of ranging movement could follow. A decisive move above $32.04 resistance would signal a potential shift upward, but a break below $27.7 support would confirm continued bearish momentum.

Anton Kharitonov, analyst at Traders Union, sees Hims & Hers Health under intensifying legal and regulatory pressure following the FTC lawsuit. The stock displays persistent bearish momentum with key supports now in focus. Technically, downside continuation is favored as momentum and sentiment remain firmly negative. "Unless $32.04 is reclaimed, I remain defensive and expect further downside risk."

Earlier, analysts noted that Hims & Hers Health maintained underlying technical support and a mildly bullish momentum outlook, even as ongoing selling pressure persisted. The recent FTC lawsuit and subsequent legal investigations introduce a new layer of operational and regulatory risk, making a break below $27.70 support a critical downside risk for traders to monitor in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.